[{"id":"a334d333-a3ba-49e5-a0c5-4e85464ed3d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470489","created_at":"2026-03-28T01:44:21.005Z","updated_at":"2026-03-28T01:44:21.005Z","phase":"Phase 2","brief_title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","source_id_and_acronym":"NCT07470489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 09/30/2026","start_date":" 09/30/2026","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2026-03-13"},{"id":"f19011bc-a0f1-46bf-8979-e38379c2fbd2","acronym":"NEO-COMBATXL","url":"https://clinicaltrials.gov/study/NCT06902376","created_at":"2025-06-07T14:40:06.805Z","updated_at":"2025-06-07T14:40:06.805Z","phase":"Phase 1","brief_title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","source_id_and_acronym":"NCT06902376 - NEO-COMBATXL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/03/2025","start_date":" 06/03/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-06-04"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"80d8b063-fde0-450d-9857-f3e96ed43e05","acronym":"STELLAR-305","url":"https://clinicaltrials.gov/study/NCT06082167","created_at":"2023-10-14T01:13:13.670Z","updated_at":"2025-02-25T16:19:12.483Z","phase":"Phase 2/3","brief_title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06082167 - STELLAR-305","lead_sponsor":"Exelixis","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/01/2028","primary_completion_date":" 08/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-01-31"},{"id":"3e93e97f-f870-4d69-bd14-6657626fe0db","acronym":"STELLAR-303","url":"https://clinicaltrials.gov/study/NCT05425940","created_at":"2022-06-21T23:54:39.625Z","updated_at":"2024-07-02T16:35:14.190Z","phase":"Phase 3","brief_title":"Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05425940 - STELLAR-303","lead_sponsor":"Exelixis","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)"],"overall_status":"Recruiting","enrollment":" Enrollment 874","initiation":"Initiation: 09/07/2022","start_date":" 09/07/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-03-19"},{"id":"e993ce91-2679-4a51-a9c2-2a1e49731991","acronym":"","url":"https://clinicaltrials.gov/study/NCT03845166","created_at":"2021-01-18T18:59:01.227Z","updated_at":"2024-07-02T16:35:18.886Z","phase":"Phase 1","brief_title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","source_id_and_acronym":"NCT03845166","lead_sponsor":"Exelixis","biomarkers":" HER-2 • KRAS • BRAF • NRAS • MSI","pipe":" | ","alterations":" BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HR positive • MSI-H/dMMR • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Bavencio (avelumab) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-02-19"}]